Lupin Of India Expects U.S. FDA Clearance For Problem Plant In March
This article was originally published in PharmAsia News
Executive Summary
India's Lupin says it expects to have its dispute with U.S. FDA resolved by March, based on an upcoming agency inspection of a questionable plant